LEO Pharma

LEO Pharma A/S indlicenserer lovende ny lægemiddelkandidat fra JW Pharmaceutical til oral behandling af atopiske dermatitis

Del
LEO Pharma får eksklusivrettigheder til at udvikle og kommercialisere JW1601 på det globale marked ekskl. Korea. JW1601 er en ny lægemiddelkandidat beregnet til oral behandling af atopisk dermatitis. JW Pharmaceutical modtager op til 402 mio. USD på forhånd og i milepælsbetalinger. Udover milepælsbetalinger vil der blive tildelt royalty.

Seoul, Korea og Ballerup, Danmark, den 24. august 2018 - JW Pharmaceutical ("JWP") og LEO Pharma A/S ("LEO Pharma") meddelte i dag, at de har underskrevet en global licensaftale omkring JWPs nye lægemiddelkandidat til atopisk dermatitis, JW1601. LEO Pharma, en global leder inden for medicinsk dermatologi, vil få enerettigheder til at udvikle og kommercialisere JW1601 globalt med undtagelse af Korea, hvor JWP opretholder sin eksklusivitet.

JWP modtager 17 mio. USD som forhåndsbetaling og trinvise udviklings- og salgsmilestonebetalinger i en sum på op til 385 mio. USD. I alt vil JWP modtage op til US $ 402 millioner. Udover milepælsbetalingerne vil JWP modtage op til tocifret royalty baseret på nettoomsætningen.

JW1601 er en innovativ lægemiddelkandidat udviklet af ​​JWPs forsknings- og udviklingsdatterselskab C&C Research Laboratories. I maj 2017 erhvervede JWP de globale eksklusive rettigheder til at udvikle og kommercialisere JW1601 og planlægger at indsende Investigational New Drug-ansøgning (IND) til klinisk fase 1 inden for dette år.

JW1601 har en dobbelt virkningsmekanisme, der blokerer aktivering og migration af immuncellerne, der forårsager atopisk dermatitis ved selektivt at virke på histamin H4-receptoren og hæmme histamin-signalering, der forårsager kløe. Lægemidlet forventes at vise god effekt, fordi den har både har anti-kløe og anti-inflammatorisk virkning. Stoffet forventes også at demonstrere en god sikkerhedsprofil på grund af dens høje selektivitet overfor H4-receptoren.

"Vi ser et stort behov for at finde sikre og effektive orale behandlinger til personer med atopisk dermatitis. Det er derfor med stor glæde, at indgår denne aftale med JW Pharmaceutical omkring deres nye atopiske dermatitis-lægemiddelkandidat JW1601. På LEO Pharma søger vi løbende at udvide vores pipeline med nye innovative lægemiddelkandidater, altid med det ultimative mål at bringe livsforbedrende lægemidler til de mange patienter, vi hjælper. JW1601 passer perfekt ind i vores eksisterende pipeline, der blandt andet rummer biologiske lægemidler i fase III (Tralokinumab) og fase I (LP0145) og vores topikale Delgocitinib, der i øjeblikket i fase II ", siger Kim Kjoeller, Executive Vice President, Global R&D, LEO Pharma.

Kyoung June Lee, Executive Vice President, Chief of Drug Discovery Center udtalte; "Vi finder det meget positivt, at LEO Pharma, en global leder inden for medicinsk dermatologi, anerkender værdien af ​​JW1601. Vi har stor tillid til en vellykket udvikling og global kommercialisering af JW1601, og vi ser LEO Pharma som den rigtige partner for dette projekt. Hos JWP vil vi gøre vores bedste, så de andre innovative nye lægemiddelkandidater under udvikling hos JWP også kommer til at vise konkrete resultater. "

- SLUT -

Kontakter

Media Contacts:


Head of Global External Communication
Henrik Kyndlev
hdtdk@leo-pharma.com
TEL +45 3140 6180

Corporate Communications Manager
Maia Fredtoft Soechting
mfddk@leo-pharma.com
TEL +45 3119 3559

Information om LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

ABOUT JW PHARMACEUTICAL CORPORATION
JW Pharmaceutical Corporation has been leading Korean medicine and medical supplies market over its 70 years of history. The company focuses on the field of research and development of anti-cancer drug and etc.; manufacture and sales of hospital fluid, antibiotic and other ethical pharmaceuticals.
JW Pharmaceutical Corporation was founded in 1945, and is listed on the Korea Exchange Market under the symbol "001060 ".

More information is available at http://www.jw-pharma.co.kr/pharma/en/main.jsp.

ABOUT LEO PHARMA
LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 130 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 5,200 people worldwide. For more information, visit www.leo-pharma.com or follow us on LinkedIn: www.linkedin.com/company/leo-pharma.

ABOUT JW1601
JW1601 is an orally available histamine H4 receptor inverse agonist with anti-pruritic and anti-inflammatory dual effect. It shows anti-chemotactic activity in eosinophil shape change and therapeutic effect in spontaneous NC/Nga AD model. JW1601 is currently conducting pre-clinical toxicity study and looking for phase 1 IND submission in 2018 in Korea.

 

Følg pressemeddelelser fra LEO Pharma

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra LEO Pharma

LEO Pharma announces positive phase 3 head-to-head data results from DELTA FORCE trial comparing delgocitinib cream with alitretinoin capsules in adults with severe chronic hand eczema (CHE)24.1.2024 08:00:00 CET | Pressemeddelelse

Delgocitinib cream demonstrated a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules as its primary outcome measure. Delgocitinib cream also demonstrated superiority to alitretinoin capsules in all key secondary outcome measures, including Investigator’s Global Assessment (IGA)-CHE treatment success, health-related quality of life (HRQoL), and a lower number of treatment-emergent adverse events. DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and topical treatment for CHE.1 With only one treatment option currently approved for severe CHE and no approved optionsfor more moderate forms of the disease, there is a considerable unmet need for patients living with CHE.

LEO Pharma announces positive outcome of DELTA 3 open-label extension trial of delgocitinib cream in the treatment of adults with moderate to severe chronic hand eczema (CHE)30.10.2023 10:00:00 CET | Pressemeddelelse

Subjects who completed the 16-week twice-daily treatment regimen of delgocitinib cream or cream vehicle in the phase 3 DELTA 1 or DELTA 2 trials were offered to immediately enroll into the 36-week DELTA 3 extension trial.1 The DELTA 3 trial evaluated the long-term safety of twice-daily as needed treatment with delgocitinib cream for up to 36 weeks in adults with moderate to severe CHE.1 The long-term safety profile of delgocitinib cream was consistent with previous results from the DELTA 1 and 2 trials. Patients who entered the DELTA 3 trial after receiving delgocitinib cream in the DELTA 1 and DELTA 2 trials maintained similar levels of symptom relief and treatment success over an additional 36-week treatment regimen.

LEO Pharma provides update on the development program for izuforant20.10.2023 09:43:02 CEST | Pressemeddelelse

The Phase 2a/b international trial to evaluate the efficacy and safety of orally administered izuforant tablets compared with placebo tablets for up to 16 weeks of treatment in adults with moderate to severe AD did not meet the primary endpoint. As a result, LEO Pharma ends the program for izuforant and terminates the license agreement with JW Pharmaceutical. LEO Pharma remains committed to delivering value for patients living with atopic dermatitis and other skin diseases.

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
HiddenA line styled icon from Orion Icon Library.Eye